source
- Coultreon banks $125M to support testing of former Galapagos immune drugBacked by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.BioPharma Dive · 3mo ago↗ source
- Adaptyv Bio reveals latest results in protein design competitionRIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…Endpoints · 3mo ago↗ source
- Predicting consequences of new hepatitis B vaccine recsNew data on public trust in science, AI and mental health, and other news from Morning RoundsSTAT · 3mo ago